Related Experiment Video
Updated: Apr 26, 2026
06:46
Optimized Minimally Invasive Transscleral Subretinal Injection Technique in Mouse
Published on: July 25, 2025
1.4K
An arched micro-injector (ARCMI) for innocuous subretinal injection.
Yong Sung You1, Chang Yeol Lee2, Chengguo Li2
1Nune Eye Hospital, Seoul, Republic of Korea.
Plos One
|August 12, 2014
Summary
Researchers developed an Arched Micro-injector (ARCMI) for precise subretinal drug delivery. This innovative device minimizes retinal tissue damage, offering a safer approach for treating blinding ocular diseases.
Area of Science:
- Ophthalmology
- Biomedical Engineering
- Drug Delivery Systems
Background:
- Retinal disorders are a leading cause of blindness.
- The blood retinal barrier (BRB) presents challenges for ocular drug delivery.
- Subretinal drug delivery is a promising strategy for treating retinal diseases like hemorrhage.
Purpose of the Study:
- To develop an Arched Micro-injector (ARCMI) for subretinal drug delivery.
- To achieve minimal retinal tissue damage during subretinal injections.
- To optimize ARCMI design for effective and safe ocular drug administration.
Main Methods:
- Fabrication of ARCMIs using reverse drawing lithography, controlled airflow, and electroplating.
- Optimization of ARCMI features (curvature, tip bevel, dimensions) through in-vitro testing.
- Ex-vivo validation using indocyanine green injection in porcine eyes.
Main Results:
- ARCMIs were successfully fabricated with specific dimensions and curvature for minimal tissue interaction.
- In-vitro and ex-vivo studies confirmed the ARCMI's capability for precise subretinal injection.
- No significant retinal tissue damage or hemorrhage was observed during subretinal delivery.
Conclusions:
- The developed Arched Micro-injector (ARCMI) enables safe and effective subretinal drug delivery.
- ARCMI technology holds potential for improved treatment of blinding retinal diseases.
- This approach minimizes iatrogenic damage, enhancing therapeutic outcomes in ophthalmology.
